ID: ALA5285975

Max Phase: Preclinical

Molecular Formula: C37H51NO9

Molecular Weight: 653.81

Associated Items:

Representations

Canonical SMILES:  CC(C)=C[C@H]1O[C@H]2[C@H]3O[C@@]34[C@@H](O[C@@H]2C(C)(C)O1)[C@H](O)C[C@@]1(C)[C@@]4(O)CC[C@H]2C[C@@]3(O)c4c(CC5OC5(C)C)cccc4N[C@@]3(O)[C@@]21C

Standard InChI:  InChI=1S/C37H51NO9/c1-18(2)14-24-43-26-28(31(5,6)46-24)44-27-22(39)17-32(7)33(8)20(12-13-35(32,41)36(27)29(26)47-36)16-34(40)25-19(15-23-30(3,4)45-23)10-9-11-21(25)38-37(33,34)42/h9-11,14,20,22-24,26-29,38-42H,12-13,15-17H2,1-8H3/t20-,22+,23?,24-,26+,27-,28-,29+,32+,33-,34+,35-,36-,37+/m0/s1

Standard InChI Key:  IDILDTWSMXAWQK-OYSVWAFASA-N

Associated Targets(Human)

Acyl coenzyme A:cholesterol acyltransferase 1 857 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Acyl coenzyme A:cholesterol acyltransferase 2 288 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 653.81Molecular Weight (Monoisotopic): 653.3564AlogP: 3.42#Rotatable Bonds: 3
Polar Surface Area: 145.70Molecular Species: NEUTRALHBA: 10HBD: 5
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 5#RO5 Violations (Lipinski): 1
CX Acidic pKa: 10.97CX Basic pKa: CX LogP: 3.50CX LogD: 3.50
Aromatic Rings: 1Heavy Atoms: 47QED Weighted: 0.24Np Likeness Score: 1.69

References

1. Bhattacharjee P, Rutland N, Iyer MR..  (2022)  Targeting Sterol O-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential.,  65  (24.0): [PMID:36473091] [10.1021/acs.jmedchem.2c01265]

Source